Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (181-190 of 259) with videos related to

Pageof 26
Sort By:
NPJ Breast Cancer|July 20, 2022
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Lieveke Ameye, Samuel Martel, et al.
The Lancet. Oncology|February 1, 2024
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendationsIcro Meattini, Carlotta Becherini, Saverio Caini, et al.
Journal of the National Cancer Institute|February 5, 2025
Prognostic implications of risk definitions from the monarchE and NATALEE trialsLuca Arecco, Eva Blondeaux, Marco Bruzzone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2018
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA StudyMartin Filipits, Urania Dafni, Michael Gnant, et al.
Journal of the National Cancer Institute|April 22, 2016
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized TrialAmir Sonnenblick, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
Breast Cancer Research : BCR|June 13, 2025
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric studyKaren Van Baelen, Ha-Linh Nguyen, François Richard, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 5, 2013
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTOGeraldine Gebhart, Cristina Gámez, Eileen Holmes, et al.
Oncology and Therapy|August 5, 2020
Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 MonthsBegoña de Las Heras, Kamal S Saini, Frances Boyle, et al.
Plos One|July 26, 2016
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast CancerMichail Ignatiadis, Dimitrios Zardavas, Marc Lemort, et al.
Breast Cancer Research and Treatment|October 25, 2023
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in BelgiumMariana Brandão, Diogo Martins-Branco, Claudia De Angelis, et al.
Pageof 26

Showing results (181-190 of 259) with videos related to

Sort By:
Pageof 26
NPJ Breast Cancer|July 20, 2022
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Lieveke Ameye, Samuel Martel, et al.
The Lancet. Oncology|February 1, 2024
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendationsIcro Meattini, Carlotta Becherini, Saverio Caini, et al.
Journal of the National Cancer Institute|February 5, 2025
Prognostic implications of risk definitions from the monarchE and NATALEE trialsLuca Arecco, Eva Blondeaux, Marco Bruzzone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2018
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA StudyMartin Filipits, Urania Dafni, Michael Gnant, et al.
Journal of the National Cancer Institute|April 22, 2016
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized TrialAmir Sonnenblick, Evandro de Azambuja, Dominique Agbor-Tarh, et al.
Breast Cancer Research : BCR|June 13, 2025
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric studyKaren Van Baelen, Ha-Linh Nguyen, François Richard, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 5, 2013
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTOGeraldine Gebhart, Cristina Gámez, Eileen Holmes, et al.
Oncology and Therapy|August 5, 2020
Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 MonthsBegoña de Las Heras, Kamal S Saini, Frances Boyle, et al.
Plos One|July 26, 2016
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast CancerMichail Ignatiadis, Dimitrios Zardavas, Marc Lemort, et al.
Breast Cancer Research and Treatment|October 25, 2023
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in BelgiumMariana Brandão, Diogo Martins-Branco, Claudia De Angelis, et al.
Pageof 26